Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Needham Upgrades Haemonetics to Buy, Announces $112 Price Target

Author: Benzinga Newsdesk | June 12, 2024 05:30am
Needham analyst Mike Matson upgrades Haemonetics (NYSE:HAE) from Hold to Buy and announces $112 price target.

Posted In: HAE